Conditionally Replicative Adenovirus with Tropism Expanded towards Integrins Inhibits Osteosarcoma Tumor Growth in Vitro and in Vivo

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 61-67

  Witlox, Adhiambo M ^a   Van Beusechem, Victor W ^a   Molenaar, Bonnie ^a   Bras, Hans ^b   Schaap, Gerard R ^b   Alemany, Ramon ^c,d   Curiel, David T ^a,d   Pinedo, Herbert M ^a   Wuisman, Paul I J M ^a   Gerritsen, Winald R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; BETA5 INTEGRIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN; ONCOLYTIC VIRUS; RETINOBLASTOMA PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL ASSAY; CELL KILLING; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; FEMALE; FLOW CYTOMETRY; GENE INSERTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; TARGET CELL; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; CELL SURVIVAL; FEMALE; GENE THERAPY; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; MICE; MICE, NUDE; OLIGOPEPTIDES; OSTEOSARCOMA; RECEPTORS, VITRONECTIN; RETINOBLASTOMA PROTEIN; SALVAGE THERAPY; TROPISM; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1642453767     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0609-03     Document Type: Article

References (35)

1. Renard, A. J., Veth, R. P., Schreuder, H. W., Pruszczynski, M., Bokkerink, J. P., van Hoesel, Q. G., and van Der Staak, F. J. Osteosarcoma: oncologic and functional results. A single institutional report covering 22 years. J. Surg. Oncol., 72: 124-129, 1999.
2. Lindner, N. J., Ramm, O., Hillmann, A., Roedl, R., Gosheger, G., Brinkschmidt, C., Juergens, H., and Winkelmann, W. Limb salvage and outcome of osteosarcoma. The University of Muenster experience. Clin. Orthop., 83-89, 1999.
3. Link, M. P., Goorin, A. M., Horowitz, M., Meyer, W. H., Belasco, J., Baker, A., Ayala, A., and Shuster, J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop., 8-14, 1991.
4. Bacci, G., Briccoli, A., Ferrari, S., Longhi, A., Mercuri, M., Capanna, R., Donati, D., Lari, S., Forni, C., and DePaolis, M. Neoadjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of the Rizzoli's 4th protocol. Eur. J. Cancer, 37: 2030-2039, 2001.
5. Bacci, G., Ferrari, S., Longhi, A., Forni, C., Bertoni, F., Fabbri, N., Zavatta, M., and Versari, M. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J. Chemother., 13: 93-99, 2001.
6. Longhi, A., Fabbri, N., Donati, D., Capanna, R., Briccoli, A., Biagini, R., Bernini, G., Ferrari, S., Versari, M., and Bacci, G. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J. Chemother., 13: 324-330, 2001.
7. Sluga, M., Windhager, R., Lang, S., Heinzl, H., Bielack, S., and Kotz, R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin. Orthop., 120-127, 1999.
8. Ko, S. C., Cheon, J., Kao, C., Gotoh, A., Shirakawa, T., Sikes, R. A., Karsenty, G., and Chung, L. W. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models, Cancer Res., 56: 4614-4619, 1996.
9. Xu, H. J., Zhou, Y., Seigne, J., Perng, G. S., Mixon, M., Zhang, C., Li, J., Benedict, W. F., and Hu, S. X. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res., 56: 2245-2249, 1996.
10. Worth, L. L., Jia, S. F., Zhou, Z., Chen, L., and Kleinerman, E. S. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res., 6: 3713-3718, 2000.
11. Alemany, R., Balague, C., and Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 18: 723-727, 2000.
12. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
13. Hallenbeck, P. L., Chang, Y. N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y. L. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther., 10: 1721-1733, 1999.
14. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
15. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K., and Kyritsis, A. P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12, 2000.
16. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
17. Douglas, J. T., Kim, M., Sumerel, L. A., Carey, D. E., and Curiel, D. T. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res., 61: 813-817, 2001.
18. Grill, J., van Beusechem, V. W., Van Der Valk, P., Dirven, C. M., Leonhart, A., Pherai, D. S., Haisma, H. J., Pinedo, H. M., Curiel, D. T., and Gerritsen, W. R. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res., 7: 641-650, 2001.
19. Li, Y., Pong, R. C., Bergelson, J. M., Hall, M. C., Sagalowsky, A. I., Tseng, C. P., Wang, Z., and Hsieh, J. T. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res., 59: 325-330, 1999.
20. Wesseling, J. G., Bosma, P. J., Krasnykh, V., Kashentseva, E. A., Blackwell, J. L., Reynolds, P. N., Li, H., Parameshwar, M., Vickers, S. M., Jaffee, E. M., Huibregtse, K., Curiel, D. T., and Dmitriev, I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther., 8: 969-976, 2001.
21. Cripe, T. P., Dunphy, E. J., Holub, A. D., Saini, A., Vasi, N. H., Mahller, Y. Y., Collins, M. H., Snyder, J. D., Krasnykh, V., Curiel, D. T., Wickham, T. J., DeGregori, J., Bergelson, J. M., and Currier, M. A. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res., 61: 2953-2960, 2001.
22. Witlox, M. A., van Beusechem, V. W., Grill, J., Haisma, H. J., Schaap, G., Bras, J., Van Diest, P., De Gast, A., Curiel, D. T., Pinedo, H. M., Gerritsen, W. R., and Wuisman, P. I. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med., 4: 510-516, 2002.
23. Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., and Curiel, D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol., 72: 9706-9713, 1998.
24. Feugeas, O., Guriec, N., Babin-Boilletot, A., Marcellin, L., Simon, P., Babin, S., Thyss, A., Hofman, P., Terrier, P., Kalifa, C., Brunat-Mentigny, M., Patricot, L. M., and Oberling, F. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J. Clin. Oncol., 14: 467-472, 1996.
25. Lamfers, M. L., Grill, J., Dirven, C. M., van Beusechem, V. W., Geoerger, B., Van Den Berg, J., Alemany, R., Fueyo, J., Curiel, D. T., Vassal, G., Pinedo, H. M., Vandertop, W. P., and Gerritsen, W. R. Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radio-therapy. Cancer Res., 62: 5736-5742, 2002.
26. Billiau, A., Edy, V. G., Heremans, H., Van Damme, J., Desmyter, J., Georgiades, J. A., and De Somer, P. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob. Agents Chemother., 12: 11-15, 1977.
27. Rhim, J. S., Putman, D. L., Arnstein, P., Huebner, R. J., and McAllister, R. M. Characterization of human cells transformed in vitro by N-methyl-N′-nitro-N-nitrosoguanidine. Int. J. Cancer, 19: 505-510, 1977.
28. Fogh, J., Wright, W. C., and Loveless, J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. (Bethesda), 58: 209-214, 1977.
29. Rochet, N., Dubousset, J., Mazeau, C., Zanghellini, E., Farges, M. F., de Novion, H. S., Chompret, A., Delpech, B., Cattan, N., Frenay, M., and Gioanni, J. Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int. J. Cancer, 82: 282-285, 1999.
30. van Beusechem, V. W., van den Doel, P. B., Grill, J., Pinedo, H. M., and Gerritsen, W. R. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res., 62: 6165-6171, 2002.
31. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res., 7: 120-126, 2001.
32. van den Bergh Weerman, M. A., and Dingemans, K, P, Rapid deparaffinization for electron microscopy. Ultrastruct. Pathol., 7: 55-57, 1984.
33. Benassi, M. S., Molendini, L., Gamberi, G., Ragazzini, P., Sollazzo, M. R., Merli, M., Asp, J., Magagnoli, G., Balladelli, A., Bertoni, F., and Picci, P. Alteration of pRb/pl6/cdk4 regulation in human osteosarcoma. Int. J. Cancer, 84: 489-493, 1999.
34. Kuppen, P. J., van der Eb, M. M., Jonges, L. E., Hagenaars, M., Hokland, M. E., Nannmark, U., Goldfarb, R. H., Basse, P. H., Fleuren, G. J., Hoeben, R. C., and van de Velde, C. J. Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells of adenoviruses in colorectal cancer. Histochem. Cell Biol., 115: 67-72, 2001.
35. Reid, T., Warren, R., and Kirn, D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther., 9: 979-986, 2002.